FULC · NASDAQ · Biotechnology

Fulcrum Therapeutics (FULC)

Maintains small-molecule gene-regulation capabilities while reviewing strategic alternatives.

$3.89
Pre-market+0.04 (+1.17%)
At close$3.85(−0.65%)

Something off on this page? Send us feedback.

Next report
Oct 29, 2026
in 56 days
EPS estimate
−$0.13
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

May '25Jul '25Oct '25Feb '26Apr '26Jul '26Jul '26Oct '26
Reported−$0.28−$0.28−$0.31−$0.31−$0.25−$0.21−$0.34Pending
Estimate−$0.29−$0.29−$0.29−$0.31−$0.31−$0.24−$0.24−$0.13
Surprise+3.4%+3.4%−6.9%0.0%+19.4%+13.7%−39.7%

RevenueReportedEstimate

May '25Jul '25Oct '25Feb '26Apr '26Jul '26Jul '26Oct '26
ReportedPending
Estimate
Surprise

History

DateEstimateReportedSurprise
Oct 2026−$0.13
Jul 2026−$0.24−$0.34−39.7%
Jul 2026−$0.24−$0.21+13.7%
Apr 2026−$0.31−$0.25+19.4%
Feb 2026−$0.31−$0.310.0%

The latest year is open to everyone — the 31 quarters behind it read with an account.

Sign in
Oct 2025
Jul 2025
May 2025
Feb 2025
Nov 2024
Jul 2024
May 2024
Feb 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Aug 2021
May 2021
Mar 2021
Nov 2020
Aug 2020
May 2020
Mar 2020
Nov 2019
Aug 2019
Mar 2019
Dec 2018
Sep 2018
Jun 2018
Mar 2018
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Oct 29, 2026−$0.13
Jul 31, 2026−$0.24−$0.34−39.7%+3.6%
Jul 30, 2026−$0.24−$0.21+13.7%+2.8%
Apr 27, 2026−$0.31−$0.25+19.4%−3.6%
Feb 24, 2026−$0.31−$0.310.0%+4.7%

The latest year is open to everyone — the 31 quarters behind it read with an account.

Sign in
Oct 29, 2025
Jul 29, 2025
May 1, 2025
Feb 25, 2025
Nov 13, 2024
Jul 31, 2024
May 13, 2024
Feb 27, 2024
Nov 7, 2023
Aug 3, 2023
May 15, 2023
Mar 9, 2023
Nov 8, 2022
Aug 11, 2022
May 9, 2022
Mar 3, 2022
Nov 4, 2021
Aug 10, 2021
May 6, 2021
Mar 4, 2021
Nov 10, 2020
Aug 11, 2020
May 13, 2020
Mar 5, 2020
Nov 14, 2019
Aug 26, 2019
Mar 31, 2019
Dec 31, 2018
Sep 30, 2018
Jun 30, 2018
Mar 31, 2018